Ghaderi Amir, Bussu Anna, Tsang Catherine, Jafarnejad Sadegh
Department of Addiction Studies, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Department of Psychiatry, School of Medicine, Kashan University of Medical Science, Kashan, Iran.
Eur J Clin Pharmacol. 2019 Mar;75(3):289-301. doi: 10.1007/s00228-018-2595-1. Epub 2018 Nov 16.
To conduct a systematic review and meta-analysis of published randomised controlled trials on the efficacy of NAC supplementation on positive and negative syndrome scale in schizophrenia.
A meta-analysis was conducted, and studies were identified by a search of electronic databases from inception to May 2018. Combined and stratified analyses were used.
Seven trials were identified, and data from n = 447 participants were included. Pooled analysis showed improvement of positive and negative syndrome scale following NAC treatment compared with placebo, for total (SMB = - 0.96) [95% CI - 1.69, - 0.24; P = 0.009], general (SMB = - 1.04) [95% CI - 1.80, - 0.27; P = 0.008] and negative (SMB = - 0.73) [95% CI - 1.29, - 0.17; P = 0.01] scores, respectively. Significant heterogeneity was found, and subgroup analysis showed significant reductions in studies with a treatment duration of ≤ 24 weeks, with a considerable effect size on total, general, and negative scores (Total SMD = - 0.83; General SMD = - 0.67; Negative SMD = - 1.09) following NAC.
NAC improved all aspects of positive and negative syndrome scale in schizophrenic populations and may be more efficacious with treatment durations up to 24 weeks.
对已发表的关于补充N-乙酰半胱氨酸（NAC）治疗精神分裂症的阳性和阴性症状量表疗效的随机对照试验进行系统评价和荟萃分析。
进行荟萃分析，通过检索电子数据库确定从开始到2018年5月的研究。采用合并分析和分层分析。
共纳入7项试验，447名参与者的数据。汇总分析显示，与安慰剂相比，NAC治疗后阳性和阴性症状量表有所改善，总分（标准化均数差[SMD]=-0.96）[95%置信区间（CI）-1.69，-0.24；P=0.009]、一般症状分（SMD=-1.04）[95%CI-1.80，-0.27；P=0.008]和阴性症状分（SMD=-0.73）[95%CI-1.29，-0.17；P=0.01]。发现存在显著异质性，亚组分析显示，在治疗持续时间≤24周的研究中，NAC治疗后总分、一般症状分和阴性症状分有显著降低，效应量可观（总分SMD=-(0.83)；一般症状分SMD=-0.67；阴性症状分SMD=-1.09）。
NAC改善了精神分裂症患者阳性和阴性症状量表的各个方面，治疗持续时间达24周时可能疗效更佳。
